Erika Hamilton, MD, reviews the manageable safety profile of tucatinib plus HP maintenance therapy in HER2+ metastatic breast ...

Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with ...

At the 2026 ASCO Annual Meeting, Ajaz Khan, MD, of City of Hope, highlighted several significant developments across breast ...

Timothy Hembree, DO, PhD, discusses the benefits to patients and physicians seen with an AI-supported virtual care system ...

Tolododekin alfa (ANK-101) is a novel anchored immunotherapy that links interleukin-12 (IL-12) to aluminum hydroxide via an ...

Treatment selection for newly diagnosed metastatic clear cell renal cell carcinoma (ccRCC) continues to evolve as clinicians ...

During a live event, Sikander Ailawadhi, MD, and participants discussed sequencing and bridging therapy selection for patients with early relapsed multiple myeloma who are candidates for CAR T-cell ...

For World Brain Tumor Day on June 8, Raj Singh, MD, outlines the significant unmet needs and emerging developments in brain ...

Adding selinexor (Xpovio) to ruxolitinib (Jakafi) produced significantly greater spleen volume reduction compared with ...

CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

CDK4/6 inhibitor–based regimens represent the standard of care in the first-line treatment of women with ER-positive, ...

At the ASCO Annual Meeting, a variety of investigators presented results that could change practice for patients with rare types of melanoma and skin cancers. Several presenters h ...